UCB to squeeze out Schwarz Pharma shareholders
This article was originally published in Scrip
Executive Summary
UCB is hoping to acquire the remaining stake of Schwarz Pharma that it does not already own through a "squeeze-out" procedure. The minority shareholding, which represents 0.4% of the stock capital, has been valued at €111.44 per share by UCB with assistance from Ernst & Young.